PEDIATRIC ONCOLOGY GROUP

儿科肿瘤组

• 批准号: 6341798
• 负责人: Lori Luchtman-Jones
• 金额: $ 10.07万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-01-01 至 2002-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6341798
• 关键词: 6 thiopurine; Ewing's tumor; Hodgkin's disease; Wilms' tumor; acute leukemia; acute lymphocytic leukemia; acute myelogenous leukemia; adolescence (12-20); antineoplastics; asparaginase; astrocytoma; biological response modifiers; bone marrow transplantation; brain neoplasms; busulfan; cancer registry /resource; cancer risk; central nervous system neoplasms; child (0-11); chronic myelogenous leukemia; cis platinum compound; clinical research; clinical trial phase I; colony stimulating factor; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; cyclosporines; cytosine arabinoside; daunorubicin; deferoxamine; deoxycoformycin; dexamethasone; doxorubicin; drug screening /evaluation; enalapril; ependymoma; etoposide; fluorouracil; germ cell neoplasms; glioma; hepatoblastoma; hepatocellular carcinoma; human genetic material tag; human immunodeficiency virus 1; human subject; human therapy evaluation; human tissue; ifosfamide; interferons; interleukin 2; medulloblastoma; melphalan; metastasis; methotrexate; mitoxantrone; molecular oncology; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer relapse /recurrence; neoplasm /cancer surgery; neuroblastoma; nonHodgkin's lymphoma; osteosarcoma; paclitaxel; pediatric pharmacology; podophyllin; prednisone; retinoate; rhabdomyosarcoma; tissue resource /registry; topotecan; vincristine

The Washington University Medical Center in St. Louis is one of the 39 full member institutions, 48 affiliate, 12 consortia and 9 CCOP institutions of the Pediatric Oncology Group who has pooled their patient resources and scientific expertise to study the natural history of childhood cancer, develop and compare effective therapeutic regimens and investigate the toxicity and effectiveness of new anticancer agents in the treatment of children with cancer. Additionally tumor specimens and occasionally normal tissue and blood samples are collected to determine more about the basic cancer biology and pathology of the disease. Group studies are ongoing in epidemiology, cancer control, pharmacology and pharmacokinetics. The investigators at the Washington University Medical Center include pediatric oncologists, radiologists, radiation oncologists, cytogenetists, neurologists, surgeons, and pathologists. All children with malignant disease are placed on cooperative group protocols if they are eligible and if informed consent is obtained. Data accessioned at the time the patient is placed on study protocol, during the study, and when off therapy is submitted to the Group Statistical Office for data analysis, interpretation and eventual publication. The investigators at Washington University Medical Center serve in multiple administrative and research capacities for the Group. The diagnostic studies, pathological findings, surgical procedure and therapeutic plan for all new patients and patients who relapse are discussed at the weekly Tumor Board Conference. The Principal Investigator has a phase I contract and works with 16 other POG institutions to establish the maximum tolerated dose of a new agent along with the pharmacology and, if indicated, the biologic response of the agent.

位于圣路易斯的华盛顿大学医学中心是 39 个 正式成员机构、48 个附属机构、12 个联盟和 9 个 CCOP 儿科肿瘤学组的机构汇集了他们的患者 研究自然历史的资源和科学专业知识 儿童癌症，开发和比较有效的治疗方案 研究新型抗癌药物的毒性和有效性 患有癌症的儿童的治疗。另外肿瘤标本和 有时会收集正常组织和血液样本以确定 有关该疾病的基本癌症生物学和病理学的更多信息。团体 流行病学、癌症控制、药理学和 药代动力学。华盛顿大学医学院的研究人员 中心包括儿科肿瘤科医生、放射科医生、放射科医生 肿瘤学家、细胞遗传学家、神经学家、外科医生和病理学家。全部 患有恶性疾病的儿童被纳入合作小组协议 他们是否符合资格并且是否获得知情同意。数据 在患者接受研究方案时加入，期间 研究，以及当停止治疗时提交给小组统计 数据分析、解释和最终发布办公室。这 华盛顿大学医学中心的研究人员服务于多个 集团的行政和研究能力。诊断 研究、病理结果、手术程序和治疗计划 对于所有新患者和复发患者，每周都会进行讨论 肿瘤委员会会议。首席研究员拥有第一阶段合同 并与其他 16 个 POG 机构合作，建立了最大 新药的耐受剂量以及药理学，如果 表明，药剂的生物反应。